Oral Oncology
Volume 39, Issue 3 , Pages 269-276 , April 2003

Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential

  • M Itoh

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • ,
  • T Noutomi

      Affiliations

    • Department of Oral and Maxillofacial Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan
    • ,
  • H Toyota

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • ,
  • J Mizuguchi

      Affiliations

    • Department of Immunology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • Intractable Disease Research Center, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-3-3351-6141; fax: +81-3-3341-2941

Received 1 October 2002 ,Accepted 10 October 2002.

References 

  1. Prince S, Bailey BM. Squamous carcinoma of the tongue (review). British Journal of Oral and Maxillofacial Surgery. 1999;37:164–174
  2. Lingen MW. Understanding the biology of oral cancer and chemoprevention. CDS Review. 1998;91:24–28
  3. Leemans CR, Chiesa F, Tradati N, Snow GB. Messages from completed randomized trials in head and neck cancer. European Journal of Surgical Oncology. 1997;23:469–476
  4. Reed JC. Mechanisms of apoptosis avoidance in cancer. Current Opinion in Oncology. 1999;11:68–75
  5. Gottesman MM. Mechanisms of cancer drug resistance. Annual Review of Medicine. 2002;53:615–627
  6. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies (integrating mammalian biology). Cell. 2001;104:487–501
  7. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. European Journal of Biochemistry. 1998;254:439–459
  8. Griffith TS, Lynch DH. TRAIL (a molecule with multiple receptors and control mechanisms). Current Opinion in Immunology. 1998;10:559–563
  9. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682
  10. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation. 1999;104:155–162
  11. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Research. 1999;59:2747–2753
  12. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis (doubt no more). Biochimica et Biophysica Acta. 1998;1366:151–165
  13. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nature Reviews Cancer. 2001;1:142–150
  14. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 1997;90:1208–1216
  15. Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Research. 2000;60:3051–3057
  16. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Research. 1999;59:734–741
  17. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, et al.  p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Research. 1998;58:1593–1598
  18. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Research. 2001;61:1645–1651
  19. Noutomi T, Chiba H, Itoh M, Toyota H, Mizuguchi J. Bcl-x(L) confers multi-drug resistance in several squamous cell carcinoma cell lines. Oral Oncology. 2002;38:41–48
  20. Takada E, Toyota H, Suzuki J, Mizuguchi J. Prevention of anti-IgM-induced apoptosis accompanying G1 arrest in B lymphoma cells overexpressing dominant-negative mutant form of c-Jun N-terminal kinase 1. Journal of Immunology. 2001;166:1641–1649
  21. Itoh M, Chiba H, Noutomi T, Takada E, Mizuguchi J. Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncology. 2000;36:277–285
  22. Sheikh MS, Huang Y, Fernandez-Salas EA, el-Deiry WS, Friess H, Amundson S, et al.  The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 1999;18:4153–4159
  23. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry. 1996;271:12687–12690
  24. Gazitt Y, Shaughnessy P, Montgomery W. Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine. 1999;11:1010–1019
  25. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al.  Tschopp J.Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190–195
  26. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 1991;6:1699–1703
  27. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al.  p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807–810
  28. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Research. 1999;59:1391–1399

PII: S1368-8375(02)00114-8

doi: 10.1016/S1368-8375(02)00114-8

Oral Oncology
Volume 39, Issue 3 , Pages 269-276 , April 2003

Article Tools

* Image Usage & Resolution